| scholarly article | Q13442814 |
| P50 | author | Fredric B Kraemer | Q57026392 |
| Wen-jun Shen | Q42605986 | ||
| P2093 | author name string | Haiyan Zhang | |
| Salman Azhar | |||
| Yuan Cortez | |||
| P2860 | cites work | Role of LXRs in control of lipogenesis | Q24290548 |
| PGC-1 coactivators: inducible regulators of energy metabolism in health and disease | Q24541524 | ||
| Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting | Q24563197 | ||
| Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta | Q24598068 | ||
| Human SREBP1c expression in liver is directly regulated by peroxisome proliferator-activated receptor alpha (PPARalpha) | Q24606762 | ||
| Overexpression of Insig-1 in the livers of transgenic mice inhibits SREBP processing and reduces insulin-stimulated lipogenesis | Q24631468 | ||
| PGC-1alpha deficiency causes multi-system energy metabolic derangements: muscle dysfunction, abnormal weight control and hepatic steatosis | Q24798075 | ||
| A simple method for the isolation and purification of total lipides from animal tissues | Q25939009 | ||
| Ablation of PGC-1beta results in defective mitochondrial activity, thermogenesis, hepatic function, and cardiac performance | Q27335066 | ||
| A critical role for the peroxisome proliferator-activated receptor alpha (PPARalpha) in the cellular fasting response: the PPARalpha-null mouse as a model of fatty acid oxidation disorders | Q28116120 | ||
| Masoprocol decreases rat lipolytic activity by decreasing the phosphorylation of HSL | Q28144170 | ||
| Regulation of hepatic lipogenesis by the transcription factor XBP1 | Q28507784 | ||
| The liver X receptor (LXR) and hepatic lipogenesis. The carbohydrate-response element-binding protein is a target gene of LXR | Q28513664 | ||
| Mechanism for fatty acid "sparing" effect on glucose-induced transcription: regulation of carbohydrate-responsive element-binding protein by AMP-activated protein kinase | Q28572688 | ||
| AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice | Q28591122 | ||
| SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver | Q29547646 | ||
| Metabolic control through the PGC-1 family of transcription coactivators | Q29616509 | ||
| Effects of the obese gene product on body weight regulation in ob/ob mice | Q29617935 | ||
| The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis | Q29618429 | ||
| Nonalcoholic fatty liver disease | Q29619354 | ||
| Non-alcoholic fatty liver disease (NAFLD): why you should care, when you should worry, what you should do. | Q30401022 | ||
| Fenofibrate simultaneously induces hepatic fatty acid oxidation, synthesis, and elongation in mice | Q33553422 | ||
| Hepatic insig-1 or -2 overexpression reduces lipogenesis in obese Zucker diabetic fatty rats and in fasted/refed normal rats | Q33782820 | ||
| PPARalpha: energy combustion, hypolipidemia, inflammation and cancer | Q33805104 | ||
| Genetic control of de novo lipogenesis: role in diet-induced obesity | Q33867059 | ||
| Integrated expression profiling and genome-wide analysis of ChREBP targets reveals the dual role for ChREBP in glucose-regulated gene expression. | Q33980061 | ||
| Differing endoplasmic reticulum stress response to excess lipogenesis versus lipid oversupply in relation to hepatic steatosis and insulin resistance. | Q34166238 | ||
| Liver-specific expression of transcriptionally active SREBP-1c is associated with fatty liver and increased visceral fat mass | Q34171384 | ||
| Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome. | Q34599061 | ||
| Carbohydrate-response element-binding protein deletion alters substrate utilization producing an energy-deficient liver | Q34718729 | ||
| Nordihydroguaiaretic acid protects against high-fat diet-induced fatty liver by activating AMP-activated protein kinase in obese mice | Q42909043 | ||
| Peroxisome proliferator-activated receptor-alpha regulates lipid homeostasis, but is not associated with obesity: studies with congenic mouse lines | Q43701661 | ||
| High dietary fructose induces a hepatic stress response resulting in cholesterol and lipid dysregulation | Q44630397 | ||
| Role of adenosine monophosphate-activated protein kinase-p70 ribosomal S6 kinase-1 pathway in repression of liver X receptor-alpha-dependent lipogenic gene induction and hepatic steatosis by a novel class of dithiolethiones | Q46045008 | ||
| "New" hepatic fat activates PPARalpha to maintain glucose, lipid, and cholesterol homeostasis | Q46626411 | ||
| Peroxisome proliferator-activated receptor alpha deficiency abolishes the response of lipogenic gene expression to re-feeding: restoration of the normal response by activation of liver X receptor alpha | Q48370446 | ||
| ChREBP*Mlx is the principal mediator of glucose-induced gene expression in the liver | Q50336015 | ||
| Peroxisome proliferator-activated receptor-α agonist, Wy 14,643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis. | Q51412091 | ||
| Defect in peroxisome proliferator-activated receptor alpha-inducible fatty acid oxidation determines the severity of hepatic steatosis in response to fasting. | Q51555809 | ||
| Nonalcoholic fatty liver disease in children | Q82998081 | ||
| Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, reduces hepatic steatosis and lipid peroxidation in fatty liver Shionogi mice with hereditary fatty liver | Q83951414 | ||
| Non-alcoholic fatty liver disease | Q84849966 | ||
| Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes | Q34835012 | ||
| The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis. | Q35090416 | ||
| Dissociation of inositol-requiring enzyme (IRE1α)-mediated c-Jun N-terminal kinase activation from hepatic insulin resistance in conditional X-box-binding protein-1 (XBP1) knock-out mice | Q35709954 | ||
| Genome-wide profiling of liver X receptor, retinoid X receptor, and peroxisome proliferator-activated receptor α in mouse liver reveals extensive sharing of binding sites | Q35739204 | ||
| Sustained activation of PPARα by endogenous ligands increases hepatic fatty acid oxidation and prevents obesity in ob/ob mice | Q35790318 | ||
| Fatty acid regulation of hepatic lipid metabolism | Q35975409 | ||
| Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice | Q36479005 | ||
| Carbohydrate response element binding protein, ChREBP, a transcription factor coupling hepatic glucose utilization and lipid synthesis | Q36557194 | ||
| ChREBP, a transcriptional regulator of glucose and lipid metabolism | Q36788526 | ||
| The Scap/SREBP pathway is essential for developing diabetic fatty liver and carbohydrate-induced hypertriglyceridemia in animals | Q36869039 | ||
| Fatty liver: a novel component of the metabolic syndrome | Q36906553 | ||
| Recent advances in nonalcholic fatty liver disease | Q37137361 | ||
| Nonalcoholic fatty liver disease as a component of the metabolic syndrome | Q37140029 | ||
| GRP78 expression inhibits insulin and ER stress-induced SREBP-1c activation and reduces hepatic steatosis in mice | Q37170811 | ||
| Causes and metabolic consequences of Fatty liver | Q37250791 | ||
| Current and emerging therapies in nonalcoholic fatty liver disease | Q37310300 | ||
| AMP-activated protein kinase in the regulation of hepatic energy metabolism: from physiology to therapeutic perspectives. | Q37401935 | ||
| AMPK: an emerging drug target for diabetes and the metabolic syndrome | Q37471010 | ||
| Nonalcoholic fatty liver disease: pathology and pathogenesis | Q37676210 | ||
| Non-alcoholic fatty liver disease: the hepatic consequence of obesity and the metabolic syndrome | Q37693238 | ||
| Recent insights into fatty liver, metabolic dyslipidaemia and their links to insulin resistance | Q37768004 | ||
| Current therapeutic strategies in non-alcoholic fatty liver disease. | Q37859419 | ||
| Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment | Q37873715 | ||
| Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review. | Q37896939 | ||
| Nonalcoholic fatty liver disease: a review of the spectrum of disease, diagnosis, and therapy | Q37938804 | ||
| Peroxisome-proliferator-activated receptor-alpha (PPARalpha) deficiency leads to dysregulation of hepatic lipid and carbohydrate metabolism by fatty acids and insulin | Q38289039 | ||
| Absence of sterol regulatory element-binding protein-1 (SREBP-1) ameliorates fatty livers but not obesity or insulin resistance in Lep(ob)/Lep(ob) mice | Q38290693 | ||
| Deficiency of carbohydrate-activated transcription factor ChREBP prevents obesity and improves plasma glucose control in leptin-deficient (ob/ob) mice. | Q38313248 | ||
| Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus | Q38319698 | ||
| Peroxisomal-proliferator-activated receptor alpha activates transcription of the rat hepatic malonyl-CoA decarboxylase gene: a key regulation of malonyl-CoA level | Q38347572 | ||
| Dephosphorylation of translation initiation factor 2alpha enhances glucose tolerance and attenuates hepatosteatosis in mice | Q39975807 | ||
| Palmitoylation of ketogenic enzyme HMGCS2 enhances its interaction with PPARalpha and transcription at the Hmgcs2 PPRE. | Q40685834 | ||
| Mitochondrial and peroxisomal fatty acid oxidation in liver homogenates and isolated hepatocytes from control and clofibrate-treated rats | Q41565039 | ||
| Effect of masoprocol on carbohydrate and lipid metabolism in a rat model of Type II diabetes | Q41608502 | ||
| The unfolded protein response transducer IRE1α prevents ER stress-induced hepatic steatosis | Q41904044 | ||
| UPR pathways combine to prevent hepatic steatosis caused by ER stress-mediated suppression of transcriptional master regulators. | Q42041480 | ||
| A role for PPARalpha in the control of SREBP activity and lipid synthesis in the liver | Q42115601 | ||
| Peroxisome proliferator-activated receptor alpha target genes. | Q42414964 | ||
| P433 | issue | 1 | |
| P304 | page(s) | G72-86 | |
| P577 | publication date | 2012-10-25 | |
| P1433 | published in | American Journal of Physiology - Gastrointestinal and Liver Physiology | Q15765756 |
| P1476 | title | Nordihydroguaiaretic acid improves metabolic dysregulation and aberrant hepatic lipid metabolism in mice by both PPARα-dependent and -independent pathways | |
| P478 | volume | 304 |
| Q37638473 | Acarbose, 17-α-estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males |
| Q58101515 | Anti-Hyperlipidemic Effects of Synthetic Analogs of Nordihydroguaiaretic acid (NDGA) in Dyslipidemic Rats |
| Q33945081 | Arachidonic acid downregulates acyl-CoA synthetase 4 expression by promoting its ubiquitination and proteasomal degradation. |
| Q36338285 | DENV up-regulates the HMG-CoA reductase activity through the impairment of AMPK phosphorylation: A potential antiviral target. |
| Q64898328 | DPP-4 Inhibitor Sitagliptin Improves Cardiac Function and Glucose Homeostasis and Ameliorates β-Cell Dysfunction Together with Reducing S6K1 Activation and IRS-1 and IRS-2 Degradation in Obesity Female Mice. |
| Q35783538 | Effect of Creosote Bush-Derived NDGA on Expression of Genes Involved in Lipid Metabolism in Liver of High-Fructose Fed Rats: Relevance to NDGA Amelioration of Hypertriglyceridemia and Hepatic Steatosis |
| Q28593139 | Long chain polyunsaturated fatty acids (LCPUFAs) and nordihydroguaiaretic acid (NDGA) modulate metabolic and inflammatory markers in a spontaneous type 2 diabetes mellitus model (Stillman Salgado rats) |
| Q89138089 | MMP-2 and MMP-9 contribute to the angiogenic effect produced by hypoxia/15-HETE in pulmonary endothelial cells |
| Q37294679 | Microarray analysis of gene expression in liver, adipose tissue and skeletal muscle in response to chronic dietary administration of NDGA to high-fructose fed dyslipidemic rats |
| Q55002742 | Nordihydroguaiaretic Acid, a Lignan from Larrea tridentata (Creosote Bush), Protects Against American Lifestyle-Induced Obesity Syndrome Diet-Induced Metabolic Dysfunction in Mice. |
| Q90410805 | Nordihydroguaiaretic Acid: From Herbal Medicine to Clinical Development for Cancer and Chronic Diseases |
| Q38237620 | Paradoxical cellular effects and biological role of the multifaceted compound nordihydroguaiaretic acid |
Search more.